华法林与直接口服抗凝药在结肠镜息肉切除术后出血和血栓栓塞风险的人群分析
这项基于香港2012至2020年人群的回顾性队列研究,采用倾向评分加权比较了口服抗凝药患者结肠镜息肉切除术后的结局。阿哌沙班较华法林显著降低临床显著延迟性息肉切除术后出血和血栓栓塞风险,达比加群和利伐沙班较阿哌沙班出血与血栓栓塞风险更高。
要点
- 阿哌沙班较华法林降低息肉切除术后出血风险(aHR 0.39,95%CI 0.24-0.63,p<0.001)。
- 达比加群和利伐沙班较阿哌沙班出血风险更高(aHR 2.23和2.72)。
- 阿哌沙班较华法林降低血栓栓塞风险(aHR 0.22,95%CI 0.11-0.45)。
核心结论
- 阿哌沙班较华法林、达比加群和利伐沙班与显著更低的息肉切除术后出血和血栓栓塞风险相关,尤其在老年和右侧结肠息肉患者中。
研究设计与样本
- 研究为2012至2020年香港全港性回顾性队列研究,纳入接受口服抗凝药并行结肠镜息肉切除术的患者。
- 采用倾向评分模型及逆概率治疗加权进行华法林与DOAC以及DOAC之间的比较。
主要发现
- 阿哌沙班较华法林息肉切除术后出血风险更低(aHR 0.39,95%CI 0.24-0.63,p<0.001)。
- 达比加群(aHR 2.23,95%CI 1.04-4.77,ap=0.035)和利伐沙班(aHR 2.72,95%CI 1.35-5.48,ap=0.002)较阿哌沙班出血风险更高。
- 亚组分析中阿哌沙班在年龄≥70岁和右侧结肠息肉患者中出血风险更低。
- 阿哌沙班较华法林血栓栓塞风险更低(aHR 0.22,95%CI 0.11-0.45,p<0.001)。
- 达比加群(aHR 2.60,95%CI 1.06-6.41,ap=0.033)和利伐沙班(aHR 2.96,95%CI 1.19-7.37,ap=0.013)较阿哌沙班血栓栓塞风险更高。
关键数值与推荐
- 主要结局为临床显著延迟性息肉切除术后出血,定义为30天内需再次结肠镜止血。
- 次要结局为30天内输血需求和new thromboembolic event。
临床怎么用
- 对于接受口服抗凝药并拟行结肠镜息肉切除术的患者,阿哌沙班可能较华法林、达比加群和利伐沙班具有更低的出血和血栓栓塞风险。
- 老年患者及右侧结肠息肉患者使用阿哌沙班时出血风险尤其更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There were limited data on the risk of post-polypectomy bleeding (PPB) in patients on direct oral anticoagulants (DOAC). We aimed to evaluate the PPB and thromboembolic risks among DOAC and warfarin users in a population-based cohort. METHODS: We performed a territory-wide retrospective cohort study involving patients in Hong Kong from 2012 to 2020. Patients who received an oral anticoagulant and had undergone colonoscopy with polypectomy were identified. Propensity-score models with inverse probability of treatment weighting were developed for the warfarin-DOAC and between-DOAC comparisons. The primary outcome was clinically significant delayed PPB, defined as repeat colonoscopy requiring haemostasis within 30 days. The secondary outcomes were 30-day blood transfusion requirement and new thromboembolic event. RESULTS: Apixaban was associated with lower PPB risk than warfarin (adjusted HR (aHR) 0.39, 95% CI 0.24 to 0.63, p<0.001). Dabigatran (aHR 2.23, 95% CI 1.04 to 4.77, adjusted p (ap)=0.035) and rivaroxaban (aHR 2.72, 95% CI 1.35 to 5.48, ap=0.002) were associated with higher PPB risk than apixaban. In subgroup analysis, apixaban was associated with lower PPB risk in patients aged ≥70 years and patients with right-sided colonic polyps.For thromboembolic events, apixaban was associated with lower risk than warfarin (aHR 0.22, 95% CI 0.11 to 0.45, p<0.001). Dabigatran (aHR 2.60, 95% CI 1.06 to 6.41, ap=0.033) and rivaroxaban (aHR 2.96, 95% CI 1.19 to 7.37, ap =0.013) were associated with higher thromboembolic risk than apixaban. CONCLUSIONS: Apixaban was associated with a significantly lower risk of PPB and thromboembolism than warfarin, dabigatran and rivaroxaban, particularly in older patients with right-sided polyps.
引用
- Lau LH, Guo CL, Yip TC, et al. Risks of post-colonoscopic polypectomy bleeding and thromboembolism with warfarin and direct oral anticoagulants: a population-based analysis. Gut. 2021. PMID: 33619167. doi:10.1136/gutjnl-2020-323600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。